Periventricular anastomosis in moyamoya disease: detecting fragile collateral vessels with MR angiography

Takeshi Funaki1, Jun C Takahashi2, Kazumichi Yoshida1

  • 1Departments of 1 Neurosurgery and.

Journal of Neurosurgery
|November 28, 2015
PubMed

Insights

Periventricular anastomosis, abnormal collateral vessels in moyamoya disease, can be reliably measured using MR angiography. Higher scores for these vessels correlate with an increased risk of intracranial hemorrhage at disease onset.

Area of Science:

  • Neurology
  • Radiology
  • Vascular Medicine

Background:

  • Moyamoya disease is characterized by abnormal collateral vessels.
  • Periventricular anastomosis is a novel term for these specific collateral vessels.
  • The association between these vessels and intracranial hemorrhage requires further investigation.

Purpose of the Study:

  • To determine the reliability of measuring periventricular anastomosis using MR angiography.
  • To assess the association between periventricular anastomosis and intracranial hemorrhage in moyamoya disease patients.

Main Methods:

  • A cross-sectional study of 122 moyamoya disease patients.
  • MR angiography with sliding-thin-slab maximum-intensity-projection coronal images used for detection.
  • Periventricular anastomoses scored by subtype (lenticulostriate, thalamic, choroidal).
  • Multivariate analyses evaluated the association with hemorrhagic presentation.

Main Results:

  • Good intra- and interrater reliability (κw = 0.65 and 0.70) for scoring periventricular anastomosis.
  • Hemorrhagic presentation prevalence increased with anastomosis score (2.8% for Score 0 to 46.7% for Score 3).
  • Periventricular anastomosis score remained a significant predictor of hemorrhage after adjusting for age (OR 3.38).

Conclusions:

  • Periventricular anastomosis can be reliably scored using MR angiography.
  • A significant association exists between periventricular anastomosis score and hemorrhagic presentation in moyamoya disease.
  • Further prospective studies are needed to validate its clinical utility as a hemorrhage predictor.